SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Drugs >

Abbvie (ABBV)

ABBV RSS Feed
Add ABBV Price Alert      Hide Sticky   Hide Intro
Moderator: DewDiligence
Search This Board: 
Last Post: 11/6/2017 12:26:43 PM - Followers: 42 - Board type: Free - Posts Today: 0
SureTrader
Interactive Brokers Advertisement
ABBV
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ABBV News: Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting... 09:26 AM
ABBV News: AbbVie to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference 11/15/2017 07:00:00 AM
ABBV News: Statement of Changes in Beneficial Ownership (4) 11/13/2017 05:28:05 PM
ABBV News: Statement of Changes in Beneficial Ownership (4) 11/13/2017 05:27:12 PM
ABBV News: Quarterly Report (10-q) 11/07/2017 11:30:38 AM
News News Alert: Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting... 11/21/2017 09:26:00 AM
PostSubject
#332  Sticky Note ABBV slide set (70 pages) on long-term outlook: DewDiligence 10/27/17 08:41:06 AM
#334   ABBV buy 92.62 stocktrademan 11/06/17 12:26:43 PM
#333   Transcript of ABBV 3Q17 CC: DewDiligence 10/30/17 11:38:47 AM
#332   ABBV slide set (70 pages) on long-term outlook: DewDiligence 10/27/17 08:41:06 AM
#331   ABBV 3Q17 results: DewDiligence 10/27/17 08:40:55 AM
#330   ABBV places bet on “I-N” for AD: #msg-135656625. DewDiligence 10/24/17 02:26:26 PM
#329   Oh, I fully agree with you that all KarinCA 10/18/17 02:11:00 PM
#328   For now, I stand by the assertion in DewDiligence 10/18/17 02:06:44 PM
#327   True enough... but, it's still interesting to watch. KarinCA 10/18/17 01:52:29 PM
#326   The 2018 formularies for such PBMs as CVS DewDiligence 10/18/17 01:49:44 PM
#325   Was CVS’s Formulary Exclusion of Mavyret a Violation KarinCA 10/18/17 01:45:52 PM
#324   Positive phase-2b data for Upadacitinib in atopic dermatitis: #msg-134452680. DewDiligence 09/07/17 03:01:49 PM
#323   USPTO denies CHRS’ IPR on ABBV’s ‘619 patent: #msg-134452711. DewDiligence 09/07/17 03:00:58 PM
#321   FDA approves ABBV/ENTA’s Mavyret: #msg-133548596. DewDiligence 08/03/17 03:25:20 PM
#320   ABBV 2Q17 CC (edited) transcript: DewDiligence 07/29/17 09:46:51 AM
#319   European Commission approves GILD’s Vosevi and ABBV/ENTA’s Maviret, DewDiligence 07/28/17 12:15:23 PM
#317   https://www.wsj.com/articles/abbvie-ordered-to-pay-150-million-in-androgel-lawsuit-1500934708?mg=pro north40000 07/24/17 10:04:05 PM
#316   CHMP approves ABBV/ENTA’s Maviret (G/P) for HCV genotypes 1-6: DewDiligence 06/23/17 09:44:48 AM
#315   ABBV’s Upadacitinib—(f/k/a ABT-494)—JAK inhibitor succeeds in RA phase-3: DewDiligence 06/07/17 09:41:35 AM
#314   Transcript of ABBV’s !Q17 CC: DewDiligence 05/03/17 05:47:55 PM
#313   $ABBV - How AbbVie's 2020 Strategy Parallels Celgene's KarinCA 05/03/17 05:35:29 PM
#312   Totally agree, and well stocked with shares and options. stockspirit 04/28/17 01:24:19 PM
#311   Nice Hits, this one ready to bounce? PENNYMACHINE 04/28/17 01:17:37 PM
#310   The ruling is a positive for MNTA and DewDiligence 03/07/17 02:42:47 PM
#309   In A Blow To AbbVie Inc (NYSE:ABBV) Humira, trendmkr 03/06/17 02:13:13 PM
#308   ABBV authorizes new $5B buyback: DewDiligence 02/17/17 10:13:36 AM
#307   UK National Institute For Health And Care Excellence trendmkr 02/16/17 02:40:11 PM
#306   Xeljanz shows mixed outcomes in phase-4 comparisons to DewDiligence 02/16/17 01:44:13 PM
#305   FDA grants priority review for G/P regimen: #msg-128359345. DewDiligence 02/02/17 08:21:15 AM
#304   I stand corrected 4.2% yield lloyd Banks 01/31/17 04:04:46 PM
#303   You said 4% HAHAHAHAHAHAHHAAHAHHAAHHA MikeBK205 01/31/17 03:53:38 PM
#302   It will enter the MJ market when it lloyd Banks 01/27/17 08:51:21 PM
#301   CHMP approves AMGN’s Humira FoB: #msg-128199069. DewDiligence 01/27/17 10:45:34 AM
#300   ABBV reports 4Q16 results: DewDiligence 01/27/17 09:10:53 AM
#298   That's not what The Street, Cramers, Msnbs says MikeBK205 01/25/17 07:52:42 PM
#297   It isn't. You must be on the wrong board. DewDiligence 01/25/17 07:46:33 PM
#296   Why is this considered a marijuana stock? MikeBK205 01/25/17 07:06:54 PM
#295   EMA grants accelerated assessment for G/P HCV regimen: #msg-128090944. DewDiligence 01/24/17 10:17:48 AM
#294   ABBV JPM slides: DewDiligence 01/11/17 11:30:44 AM
#293   Imbruvica shows impressive activity in CLL/SLL after 5 years: DewDiligence 12/03/16 08:23:08 PM
#292   MRK’s 3-DAA HCV regimen fails to impress: #msg-126517784. DewDiligence 11/13/16 10:44:09 AM
#291   ABBV makes this bit.ly/2frudVN Stock Screen : Top dividend ValueInvestor15 11/11/16 12:55:47 PM
#290   ABBV/ENTA report 8w Glecaprevir/Pibrentasvir phase-3 data from three trials: DewDiligence 11/11/16 08:48:34 AM
#289   USPTO rules for ABBV—against CHRS—on Humira ‘166 patent: DewDiligence 11/07/16 12:35:46 PM
#288   ABBV reports 3Q16 results: DewDiligence 10/28/16 08:04:54 AM
#287   AMGN not launching Amjevita—(Humira FoB)—until 2018 or later: DewDiligence 10/27/16 06:47:26 PM
#286   Musings on GILD’s POLARIS studies of 3-DAA HCV regimen: DewDiligence 10/20/16 12:22:22 PM
#285   Leerink initiated AbbVie ABBV at Market Perform. Agree... ValueInvestor15 10/18/16 11:03:06 AM
#284   ABBV/ENTA's second-generation HCV regimen gets FDA BTD for DewDiligence 09/30/16 08:20:09 AM
#283   FDA approves AMGN’s Humira biosimilar: DewDiligence 09/23/16 07:14:06 PM
#280   2Q16 Harvoni/Viekira/Zepatier sales in US/EU/Japan: #msg-124194472. DewDiligence 07/29/16 02:34:39 PM
PostSubject